Analysts expect Evommune, Inc. to report revenue of 1.29 M for Q2 26, against a range of 1.20 M to 1.38 M. The most recent reported quarter, Q1 26, came in at 0.00, a 100.0% miss against the 755,014.29 consensus.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 10.00 M | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | 3.52 M | 0.00 | 826,763.30 | 1.38 M | 491,262.51 | 3.74 M | 0.00 | 1.32 M | 438,942.36 | 1.49 M | -290,246.19 | |||||||||||
| Low Estimate | - | 2.93 M | 0.00 | 683,265.28 | 1.20 M | 456,692.49 | 3.20 M | 0.00 | 1.17 M | 390,640.72 | 1.36 M | -349,718.07 | |||||||||||
| Consensus Estimate | - | 3.23 M | 0.00 | 755,014.29 | 1.29 M | 473,977.50 | 3.47 M | 0.00 | 1.24 M | 414,791.54 | 1.43 M | -319,982.13 |
Analysts expect Evommune, Inc. to report earnings per share of -0.64 for Q2 26, against a range of -0.68 to -0.60. The most recent reported quarter, Q1 26, came in at -0.64, a 23.8% beat against the -0.84 consensus.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -4.77 | -8.07 | -1.43 | -0.64 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | -6.07 | -0.78 | -0.78 | -0.60 | -0.70 | -0.71 | -0.68 | 0.17 | 0.48 | 1.40 | -1.93 | |||||||||||
| Low Estimate | - | -6.63 | -0.90 | -0.90 | -0.68 | -0.82 | -0.79 | -0.74 | 0.15 | 0.42 | 1.14 | -2.31 | |||||||||||
| Consensus Estimate | - | -6.35 | -0.84 | -0.84 | -0.64 | -0.76 | -0.75 | -0.71 | 0.16 | 0.45 | 1.27 | -2.12 |